BMO Capital Downgrades Alder Biopharm (ALDR) to Market Perform Following Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
SVB Leerink Downgrades Alder Biopharm (ALDR) to Market Perform Following Acquisition
September 17, 2019 4:15 AM EDTSVB Leerink analyst Marc Goodman downgraded Alder Biopharm (NASDAQ: ALDR) from Outperform to Market Perform with a price target of $20.00 (from $21.00).
For an analyst ratings summary and ratings history on Alder Biopharm click here. For more ratings news on Alder Biopharm click here.
Shares of Alder Biopharm closed at $18.50 yesterday.
... More